'Weeding the garden' lets anaplastic lymphoma kinase-positive lung cancer patients continue crizotinib

Patients taking crizotinib for anaplastic lymphoma kinase-positive non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease, according to a new study.